Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT02131376 | Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy | terminated | N/A | 26 | Indiana UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02071719 |
| Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients |
| terminated |
| — |
| 6 |
| M. LabotsOTHER |
| 1 |
| Nov 20, 2020 |
| clinicaltrials |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC(TAURUS) | terminated | Phase 2 | 58 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 27, 2020 | clinicaltrials |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 16, 2020 | clinicaltrials |
| NCT02170389 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | terminated | N/A | 5 | Roswell Park Cancer InstituteOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma | terminated | N/A | 2 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | terminated | Phase 1 / Phase 2 | 24 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | terminated | Phase 1 | 16 | Celldex TherapeuticsINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | terminated | Phase 2 | 342 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | terminated | — | 6 | Baylor College of MedicineOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00001803 | Von Hippel-Lindau Disease Genetic Epidemiology Study | terminated | — | 546 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00005655 | Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer | terminated | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00582790 | Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | terminated | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | terminated | Phase 1 | 6 | Virginia Commonwealth UniversityOTHER | 1 | Oct 24, 2019 | clinicaltrials |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | terminated | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2019 | clinicaltrials |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | terminated | Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | terminated | Phase 3 | 724 | SFJ Pharma Ltd. IIINDUSTRY | 9 | Sep 20, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 110 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection | terminated | N/A | 39 | Yale UniversityOTHER | 1 | Jul 1, 2019 | clinicaltrials |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | terminated | Phase 2 | 5 | Region SkaneOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT01195649 | Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy | terminated | — | 11 | BayerINDUSTRY | 0 | Jun 4, 2019 | clinicaltrials |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | N/A | 9 | Northwestern UniversityOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT00923390 | Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice(N1) | terminated | — | 23 | CureOneOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | terminated | Phase 3 | 77 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01502228 | PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma | terminated | N/A | 14 | Indiana UniversityOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 18 | PfizerINDUSTRY | 2 | Jan 8, 2019 | clinicaltrials |
| NCT01457131 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02026960 | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017) | terminated | N/A | 14 | Duke UniversityOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | terminated | N/A | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases | terminated | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 | 17 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2020source: clinicaltrials